Portal hypertension

Current Opinion in Gastroenterology

Volumn 16, Issue 3, 2000, Pages 282-289

  Garcia Tsao, G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; LOSARTAN; MIDAZOLAM; MIDODRINE; NITRIC OXIDE; OCTREOTIDE; ORNIPRESSIN; PLACEBO; PROPRANOLOL; SOMATOSTATIN;

ASCITES; CHRONIC LIVER DISEASE; CLINICAL TRIAL; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; META ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; REVIEW; SODIUM RETENTION; STOMACH VARICES; VEIN DILATATION;

EID: 0034463056     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200005000-00012     Document Type: Review

References (45)

1. Chronic blockade of endothelin receptors in cirrhotic rats: Hepatic and hemodynamic effects
2. Endothelial dysfunction in the intrahepatic microcirculation of the cirrhotic rat
3. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: Endothelial dysfunction in portal hypertension
4. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat
5. Bacterial translocation to lymph nodes of cirrhotic rats stimulates eNOS-derived NO pmoduction and impairs mesenteric vascular contractility
6. Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding
7. Prognostic value of early measurements of portal pressure in acute variceal bleeding
8. Portohepatic gradient and portal hemodynamics in patients with cirrhosis due to hepatites C virus infection
9. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis
10. Effect of Iosartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis
11. Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: A caution
12. Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis
13. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis
14. Low-dose midazolam sedation: An option for patients undergoing serial hepatic venous pressure measurements
15. Doppler study of mesenteric, hepatic, and portal circulation in alcoholic cirrhosis: Relationship between quantitative Doppler measurements and the severity of portal hypertension and hepatic failure
16. Hepatic arterial pulsatility index in cirrhosis: Correlation with portal pressure
17. Increased blood flow through the portal system in cirrhotic rats
18. Prevention of a first episode of variceal bleeding: Role of duplex Doppler sonographic measurement of the acute response to beta-blockers
19. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding
20. Primary prevention of bleeding from esophageal varices
21. Somatostatin alone or combined with emergency sclerotherapy in the treatment of acute esophageal variceal bleeding: A prospective randomized trial
22. Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis
23. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta-analysis
24. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: A consensus document
25. Retrograde transvenous obliteration of gastric varices
26. Combined ligation and sclerotherapy versus ligation alone for eradication of bleeding esophageal varices: A randomized and prospective trial
27. Randomized trial of ligation versus combined ligation and sclerotherapy for bleeding esophageal varices
28. The economic impact of esophageal variceal hemorrhage: Cost-effectiveness implications of endoscopic therapy
29. TIPS for prevention of recurrent bleeding in patients with cirrhosis: Meta-analysis of randomized clinical trials
30. Transjugular intrahepatic portsystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding. A meta-analysis
31. Cost analysis for the prevention of variceal rebleeding: A comparison between transjugular intrahepatic portosystemic shunt and endoscopic sclerotherapy in a selected group of Italian cirrhotic patients
32. Effects of chronic octreotide treatment on renal changes during cirrhosis in rats
33. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal haemodynamics and atrial natriuretic factor
34. Acute effects of the oral administration of midodrine, an a-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites
35. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide
36. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites
37. A prospective study of bacterial infections in patients with cirrhosis
38. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels
39. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis
40. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction
41. Chronic exposure of rat primary astrocyte cultures to manganese results in increased binding sites for the 'peripheral type' benzodiazepine receptor ligand 3H-PK 11195
42. Opiod receptor ligands in human hepatic encephalopathy
43. Helicobacter pylori, hyperammonemia and subclinical portosystemic encephalopathy: Effects of eradication
44. Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests
45. Prognostic significance of hepatic encephalopathy in patients with cirrhosis